Neoplasia · 2017 · 32 citations · 42 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyCancer Cell SignalingCancer Stem Cell BiologyCancer Stem CellsMalignant NeoplasmsSoft Tissue SarcomasTargeted TherapyCancer Stem Cell ModelsCancer Stem Cell Signaling PathwaysCancer Stem Cell TargetingCell Cycle Arrest SignalingMyxoid LiposarcomaPleomorphic LiposarcomaSoft Tissue Sarcoma TreatmentTumor Initiating Cells
Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and undifferentiated pleomorphic sarcoma (UPS) developed from transformed human mesenchymal stromal/stem cells (MSCs) to evaluate the effect of trabectedin in the cell type responsible for initiating sarcomagenesis and their derived cancer stem cells (CSC) subpopulations. We found that low nanomolar concentrations of trabectedin efficiently inhibited the growth of sarcoma-initiating cells, induced cell cycle arrest, DNA damage and apoptosis. Interestingly, trabectedin treatment repressed the expression of multiple genes responsible for the development of the CSC phenotype, including pluripotency factors, CSC markers and related signaling pathways. Accordingly, trabectedin induced apoptosis and reduced the survival of CSC-enriched tumorsphere cultures with the same efficiency that inhibits the growth of bulk tumor population. In vivo, trabectedin significantly reduced the mitotic index of MRCLS xenografts and inhibited tumor growth at a similar extent to that observed in doxorubicin-treated tumors. Combination of trabectedin with campthotecin (CPT), a chemotherapeutic drug that shows a robust anti-tumor activity when combined with alkylating agents, resulted in a very strong synergistic inhibition of tumor cell growth and highly increased DNA damage and apoptosis induction. Importantly, the enhanced anti-tumor activity of this combination was also observed in CSC subpopulations. These data suggest that trabectedin and CPT combination may constitute a novel strategy to effectively target both the cell-of-origin and CSC subpopulations in sarcoma.
42
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano, Roberta Frapolli, Cristina Belgiovine et al. · Cancer Cell · 2013 · 862 citations · Full text
Life Sciences, Immunology, Oncology +14
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano, Roberta Frapolli, Matteo Simone et al. · Cancer Research · 2010 · 263 citations · Full text
Medicine, Oncology, Pharmacology +17
Juan M. Funes, Marisol Quintero, Stephen Henderson et al. · Proceedings of the National Academy of Sciences · 2007 · 254 citations · Full text